{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:36:59Z","timestamp":1792442219865,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.jacl.2018.08.012","type":"journal-article","created":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T22:40:44Z","timestamp":1536619244000},"page":"1358-1366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal"],"prefix":"10.1016","volume":"12","author":[{"given":"Michael B.","family":"Boffa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saverio","family":"Stranges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Klar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Moriarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald F.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlys L.","family":"Koschinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jacl.2018.08.012_bib1","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2018.08.012_bib2","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1001\/jamacardio.2017.3833","article-title":"Association of lipoprotein(a) with risk of recurrent ischemic events following acute coronary syndrome: Analysis of the dal-outcomes randomized clinical trial","volume":"3","author":"Schwartz","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2018.08.012_bib3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O'Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jacl.2018.08.012_bib4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S2213-8587(17)30096-7","article-title":"Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study","volume":"5","author":"Zewinger","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jacl.2018.08.012_bib5","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.atherosclerosis.2017.06.026","article-title":"Lipoprotein(a) and coronary atheroma progression rates during long-term high-intensity statin therapy: Insights from SATURN","volume":"263","author":"Puri","year":"2017","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1016\/j.jacl.2018.08.012_bib6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1399-0004.1997.tb04342.x","article-title":"Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study","volume":"52","author":"Berg","year":"1997","journal-title":"Clin Genet"},{"issue":"14","key":"10.1016\/j.jacl.2018.08.012_bib7","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1001\/jama.283.14.1845","article-title":"Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause","volume":"283","author":"Shlipak","year":"2000","journal-title":"JAMA"},{"issue":"12","key":"10.1016\/j.jacl.2018.08.012_bib8","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1161\/ATVBAHA.113.302479","article-title":"Plasma lipoprotein(a) concentration predicts future coronary and cardiovascular events in patients with stable coronary heart disease","volume":"33","author":"Nestel","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"10.1016\/j.jacl.2018.08.012_bib9","doi-asserted-by":"crossref","first-page":"e114519","DOI":"10.1371\/journal.pone.0114519","article-title":"Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers","volume":"9","author":"Arsenault","year":"2014","journal-title":"PLoS One"},{"issue":"17","key":"10.1016\/j.jacl.2018.08.012_bib10","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2018.08.012_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1161\/01.ATV.17.2.239","article-title":"A prospective case-control study of lipoprotein(a) levels and apo(a) size and risk of coronary heart disease in Stanford Five-City Project participants","volume":"17","author":"Wild","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"6","key":"10.1016\/j.jacl.2018.08.012_bib12","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1194\/jlr.M012526","article-title":"Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study","volume":"52","author":"Lamon-Fava","year":"2011","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.jacl.2018.08.012_bib13","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors Collaboration","year":"2009","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jacl.2018.08.012_bib14","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1365-2796.2012.02592.x","article-title":"Lipoprotein(a): resurrected by genetics","volume":"273","author":"Kronenberg","year":"2013","journal-title":"J\u00a0Intern Med"},{"issue":"11","key":"10.1016\/j.jacl.2018.08.012_bib15","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"issue":"12","key":"10.1016\/j.jacl.2018.08.012_bib16","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/ijcp.12903","article-title":"Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options","volume":"70","author":"Anagnostis","year":"2016","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.jacl.2018.08.012_bib17","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacc.2018.04.060","article-title":"Lipoprotein(a) and Cardiovascular Risk Prediction Among Women","volume":"72","author":"Cook","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"10.1016\/j.jacl.2018.08.012_bib18","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1194\/jlr.R051904","article-title":"Lipoprotein (a): impact by ethnicity and environmental and medical conditions","volume":"57","author":"Enkhmaa","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2018.08.012_bib19","series-title":"Regression modeling strategies with applications to linear models, logistic and ordinal regression, and survival analysis","author":"Harrell","year":"2015"},{"issue":"11","key":"10.1016\/j.jacl.2018.08.012_bib20","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacl.2018.08.012_bib21","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1161\/ATVBAHA.116.308011","article-title":"Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States","volume":"36","author":"Varvel","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"23","key":"10.1016\/j.jacl.2018.08.012_bib22","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2018.08.012_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/MOL.0000000000000171","article-title":"'LDL-C'\u00a0= LDL-C\u00a0+ Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin\/kexin type 9 era of potent LDL-C lowering","volume":"26","author":"Yeang","year":"2015","journal-title":"Curr Opin Lipidol"},{"issue":"4","key":"10.1016\/j.jacl.2018.08.012_bib24","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/HCO.0000000000000300","article-title":"Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis","volume":"31","author":"Yeang","year":"2016","journal-title":"Curr Opin Cardiol"},{"issue":"12","key":"10.1016\/j.jacl.2018.08.012_bib25","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1161\/ATVBAHA.116.308271","article-title":"Estimating the Population Impact of Lp(a) Lowering on the Incidence of Myocardial Infarction and Aortic Stenosis-Brief Report","volume":"36","author":"Afshar","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"27","key":"10.1016\/j.jacl.2018.08.012_bib26","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1093\/eurheartj\/ehy334","article-title":"Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting","volume":"39","author":"Verbeek","year":"2018","journal-title":"Eur Heart J"},{"issue":"10155","key":"10.1016\/j.jacl.2018.08.012_bib27","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels predict cardiovascular events: An individual-patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jacl.2018.08.012_bib28","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacl.2018.08.012_bib29","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jama.2011.163","article-title":"Index event bias as an explanation for the paradoxes of recurrence risk research","volume":"305","author":"Dahabreh","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1016\/j.jacl.2018.08.012_bib30","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jclinepi.2012.06.023","article-title":"Index event bias-a numerical example","volume":"66","author":"Smits","year":"2013","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.jacl.2018.08.012_bib31","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2018.08.012_bib32","doi-asserted-by":"crossref","first-page":"480784","DOI":"10.1155\/2012\/480784","article-title":"A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis","volume":"2012","author":"Missala","year":"2012","journal-title":"Int J Rheumatol"},{"issue":"5","key":"10.1016\/j.jacl.2018.08.012_bib33","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1194\/jlr.P052209","article-title":"IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans","volume":"56","author":"Muller","year":"2015","journal-title":"J Lipid Res"},{"issue":"4","key":"10.1016\/j.jacl.2018.08.012_bib34","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"issue":"3","key":"10.1016\/j.jacl.2018.08.012_bib35","first-page":"229","article-title":"Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events","volume":"6","author":"Jaeger","year":"2009","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"24","key":"10.1016\/j.jacl.2018.08.012_bib36","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/CIRCULATIONAHA.113.002432","article-title":"Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascular disease: prospective observational multicenter study","volume":"128","author":"Leebmann","year":"2013","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jacl.2018.08.012_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/aor.12135","article-title":"Does regular lipid apheresis in patients with isolated elevated lipoprotein(a) levels reduce the incidence of cardiovascular events?","volume":"38","author":"Rosada","year":"2014","journal-title":"Artif Organs"},{"issue":"1","key":"10.1016\/j.jacl.2018.08.012_bib38","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.atherosclerosissup.2012.10.015","article-title":"Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography","volume":"14","author":"Safarova","year":"2013","journal-title":"Atheroscler Suppl"},{"issue":"20","key":"10.1016\/j.jacl.2018.08.012_bib39","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","article-title":"Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial","volume":"38","author":"Khan","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.08.012_bib40","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.plipres.2017.09.001","article-title":"The renaissance of lipoprotein(a): Brave new world for preventive cardiology?","volume":"68","author":"Ellis","year":"2017","journal-title":"Prog Lipid Res"},{"issue":"10057","key":"10.1016\/j.jacl.2018.08.012_bib41","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised\u00a0lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.jacl.2018.08.012_bib42","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.jacl.2018.08.012_bib43","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/eurheartj\/ehx462","article-title":"How to use Mendelian randomization to anticipate the results of randomized trials","volume":"39","author":"Ference","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2018.08.012_bib44","series-title":"Lessons from genetics: risk-score and novel candidates","author":"Ference","year":"2018"},{"issue":"9","key":"10.1016\/j.jacl.2018.08.012_bib45","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1194\/jlr.R053066","article-title":"Current therapies for lowering lipoprotein (a)","volume":"57","author":"van Capelleveen","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.jacl.2018.08.012_bib46","series-title":"Lipoprotein(a), PCSK9 inhibition and cardiovascular risk: insights from the Fourier Trial","author":"O'Donoghue","year":"2018"},{"key":"10.1016\/j.jacl.2018.08.012_bib47","series-title":"Lp(a) and Cardiovascular Outcomes: an Analysis from the ODYSSEY OUTCOMES Trial","author":"Bittner","year":"2018"},{"key":"10.1016\/j.jacl.2018.08.012_bib48","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein(a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res"},{"issue":"18","key":"10.1016\/j.jacl.2018.08.012_bib49","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J\u00a0Med"},{"issue":"5","key":"10.1016\/j.jacl.2018.08.012_bib50","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ahj.2014.07.028","article-title":"Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial","volume":"168","author":"Schwartz","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2018.08.012_bib51","series-title":"Are we ready to test the Lp(a) hypothesis?","author":"Tsimikas","year":"2018"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418303714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287418303714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:34:54Z","timestamp":1761831294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287418303714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":51,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["S1933287418303714"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2018.08.012","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2018.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Inc. on behalf of National Lipid Association.","name":"copyright","label":"Copyright"}]}}